STAT+: ARCH-launched Neumora stops depression program

Neumora, a biotech firm backed by ARCH, has decided to halt its depression program, signaling a significant setback in its efforts to develop new treatments for mental health conditions. This move comes amid broader industry challenges in finding effective treatments for depression, highlighting the difficulties in drug development for such complex diseases. With this decision, Neumora shifts focus to other areas, potentially redirecting resources and attention to more promising projects. This decision underscores the high stakes and often unpredictable nature of biotech research and development.